

1. Use this link to get to the UIC Research website:
[https://uicresearchirb.huronresearchsuite.com/IRB/sd/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity\[OID\[E524AE9BF6E711EC7A990282AF565000\]\]](https://uicresearchirb.huronresearchsuite.com/IRB/sd/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity[OID[E524AE9BF6E711EC7A990282AF565000]])

2. Once you log in, click the “IRB” tab at the top of the page.

UIC RESEARCH Hello, Erin O'Donnell

Dashboard COI **IRB**

Page for Erin O'Donnell

My Inbox My Reviews

My Inbox

Filter by ID Enter text to search

ID	Name	Date Created	Date Modified	State	Coordinator
STUDY2022-0771	I-CHE#3	7/5/2022 2:45 PM	7/28/2022 11:06 AM	Modifications Required	Hunter Kowalski
STUDY2021-0900-MODCR001	Modification and Continuing Review #1 for Study BMT-10: Pilot Study to Develop Methods for Clinical Pharmacokinetic Testing of Fludarabine in Patients Undergoing a Fludarabine-Based Hematopoietic Stem Cell Transplant or CAR-T Cell Therapy	7/28/2022 10:45 AM	7/28/2022 10:49 AM	Pre-Submission	System Administrator
STUDY2022-0210-MOD001	Modification / Update #1 for Study SGN35-035: A phase 1, single-blind, dose-escalation study to assess the safety and tolerability of brentuximab vedotin (ADCETRIS®) in subjects with human immunodeficiency virus (HIV)	7/18/2022 1:38 PM	7/28/2022 9:56 AM	Clarification Requested (Pre-Review)	Jovana Lombardo
STUDY2020-0316-MOD001	Modification / Update #1 for Study HEME-12: Novel Predictors of Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant	7/28/2022 8:19 AM	7/28/2022 8:25 AM	Pre-Submission	System Administrator
STUDY2022-0738	RMO-301	6/29/2022 2:01 PM	7/28/2022 5:00 AM	Clarification Requested (Pre-Review)	Laura Litman

3. Under “Active” use the drop down to search by your last name.

IRB

Submissions Meetings Reports Library Help Center

IRB

Search

Create New Study Report New Information

In-Review **Active** New Information Reports External IRB Relying Sites All Submissions Archived

Filter by PI Last Name Danciu

ID	Name	Date Modified	State	PI First Name	PI Last Name	Coordinator First Name	Coordinator Last Name	Expiration Date
STUDY2021-0230	A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer Big Ten Cancer	7/25/2022 9:18 AM	Approved	Oana	Danciu	System	Administrator	3/11/2023
STUDY2021-1417	A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLR Study)	7/22/2022 7:25 PM	Approved	Oana	Danciu	System	Administrator	12/22/2022
STUDY2020-0232	BRE-03 Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer	6/18/2022 3:09 PM	Approved	Oana	Danciu	System	Administrator	2/17/2023
STUDY2019-0528	Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337	6/18/2022 3:09 PM	Approved	Oana	Danciu	System	Administrator	3/11/2023
STUDY2018-1224	Role of HPV Infection in Resistance to Targeted Therapies in Patients with Head and Neck Cancer	6/18/2022 3:08 PM	Approved	Oana	Danciu	System	Administrator	
STUDY2017-0757	A011104/ACRIN6694: EFFECT OF PRE-OPERATIVE BREAST MRI ON SURGICAL OUTCOMES, COSTS AND QUALITY OF LIFE OF WOMEN WITH BREAST CANCER	6/18/2022 3:07 PM	Approved	Oana	Danciu	System	Administrator	3/25/2023
STUDY2016-0041	BTCRC-BRE15-016: A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer	6/18/2022 3:07 PM	Approved	Oana	Danciu	System	Administrator	12/8/2022
STUDY2015-0057	STM-03: Phase I Study of Pro-caspase Activating Compound-1 (PAC-1) in the treatment of advanced malignancies	6/18/2022 3:07 PM	Approved	Oana	Danciu	System	Administrator	12/8/2022

4. You will need to click into each of your studies individually. The “Assign PI Proxy” activity is in the activities list on the left side of the main study workspace. It looks something like this:

Pre-Submission

Last updated: 7/20/2022 11:13 AM

Next Steps

Edit Study

Printer Version

Submit

Assign Primary Contact

Assign PI Proxy

Manage Ancillary Reviews

Manage Guest List

Add Related Grant

Add Comment

Copy Submission

Discard

SPR - STUDY - (Internal)

5. After clicking on “Assign PI Proxy” the PI can click on the box under item 1. and a new window will open to display all personnel listed on the study. The PI can then select proxies from the populated list:

A proxy can perform PI responsibilities on your behalf, such as submitting the study to the IRB, modifying the study, and submitting continuing reviews.


1. Select study team members to act as proxy:

First Name	Last Name	Department
------------	-----------	------------


There are no items to display

OK

Cancel



6. After assigning the proxy, a record will be made in the history tab and the proxy's name will be listed in the study information at the top of the page:



7. You will also need to follow the same steps as above but under the "External IRB" tab.

